Squamous Non Small Cell Lung Cancer clinical trials

Explore recruiting squamous non small cell lung cancer clinical trials.

Recruiting squamous non small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Squamous Non Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III randomised, double-blind, multicentre study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 (proposed pembrolizumab biosimilar) and Keytruda in subjects with metastatic non-squamous non-small cell lung cancer

Spain, Romania, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

Italy, Czechia, Ireland, Germany, France, Spain +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer

Hungary, Romania, Spain, Poland, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 2, Open-Label Study in Subjects with Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Romania, Germany, Italy, France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Italy, Belgium, Spain, Portugal

Phase II and Phase III (Integrated) EU CTIS Study details

Squamous Non Small Cell Lung Cancer trials by city

Squamous Non Small Cell Lung Cancer in Toronto Squamous Non Small Cell Lung Cancer in Vancouver Squamous Non Small Cell Lung Cancer in Montreal Squamous Non Small Cell Lung Cancer in Calgary Squamous Non Small Cell Lung Cancer in Edmonton Squamous Non Small Cell Lung Cancer in Ottawa Squamous Non Small Cell Lung Cancer in Winnipeg Squamous Non Small Cell Lung Cancer in Quebec City Squamous Non Small Cell Lung Cancer in Hamilton Squamous Non Small Cell Lung Cancer in Kitchener Squamous Non Small Cell Lung Cancer in London Squamous Non Small Cell Lung Cancer in Halifax Squamous Non Small Cell Lung Cancer in New York Squamous Non Small Cell Lung Cancer in Los Angeles Squamous Non Small Cell Lung Cancer in Chicago Squamous Non Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease